Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent Royston A. Gray, Colin G. Stott, Nicholas A. Jones, Vincenzo Di Marzo, and Benjamin J. Whalley Cannabis and Cannabinoid Research, 2019,1-5. Doi : 10.1089/can.2019.0028 Abstract Introduction : Highly purified cannabidiol (CBD) (approved as Epidiolex in the United States) has demonstrated efficacy with an acceptable safety profile in patients with Lennox–Gastaut or Dravet syndrome in four randomized controlled trials. CBD possesses affinity for many target classes with functional effects relevant to the pathophysiology of many disease types, including epilepsy. Although the mechanism of action of CBD underlying the reduction [...]
Lire la suiteA tale of two cannabinoids : The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol Ethan Russo & Geoffrey W. Guy Medical Hypotheses, 2006, 66, 234–246 doi : 10.1016/j.mehy.2005.08.026 Summary This study examines the current knowledge of physiological and clinical effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) and presents a rationale for their combination in pharmaceutical preparations. Cannabinoid and vanilloid receptor effects as well as non-receptor mechanisms are explored, such as the capability of THC and CBD to act as anti-inflammatory substances independent of cyclo-oxygenase (COX) inhibition. CBD is demonstrated to antagonise some undesirable effects of THC including intoxication, sedation and tachycardia, while contributing analgesic, anti-emetic, [...]
Lire la suite